No products in the cart.
Roll over image to zoom in
Entresto – 49 mg+51 mg Tablet/pcs
৳ 134.00
Generic Name: Sacubitril & Valsartan
Therapeutic class: Neprilysin Inhibitor & Angiotensin Receptor Blocker (Cardiovascular Preparations)
Manufacturer: Novartis (Bangladesh) Ltd.
.Note: চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications
This combination is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
This combination is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
Dosage & Administration
The recommended starting dose of this combination is 49/51 mg twice-daily.
Double the dose of this combination after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Dose Adjustment For Patients Not Taking An ACE inhibitor Or ARB Or Previously Taking Low Doses Of These Agents.
A starting dose of 24/26 mg twice-daily is recommended for patients not currently taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) and for patients previously taking low doses of these agents. Double the dose of this combination every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Sacubitril & Valsartan is contraindicated with concomitant use of an angiotensin-converting enzyme (ACE) inhibitor. If switching from an ACE inhibitor to Sacubitril & Valsartan allow a washout period of 36 hours between administration of the two drugs.
Side Effects
Clinically significant adverse reactions that appear in other sections of the labeling include: Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia
Pregnancy & Lactation
Pregnancy: Advise female patients of childbearing age about the consequences of exposure to this combination during pregnancy. Discuss treatment options with women planning to become pregnant. Ask patients to report pregnancies to their physicians as soon as possible
Lactation: There is no information regarding the presence of sacubitril/valsartan in human milk, the effects on the breastfed infant, or the effects on milk production. Sacubitril/valsartan is present in rat milk. Because of the potential for serious adverse reactions in breastfed infants from exposure to sacubitril/valsartan, advise a nursing woman that breastfeeding is not recommended during treatment with sacubitril/valsartan.
Use in Special Populations
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly ( ≥ 65 years) or very elderly ( ≥ 75 years) patients compared to the overall population
Renal Impairment:
- Severe: A starting dose of 24/26 mg twice-daily is recommended for patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). Double the dose of Sacubitril & Valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
- Mild or moderate: No starting dose adjustment is needed for mild or moderate renal impairment.
Hepatic Impairment:
- Moderate: A starting dose of 24/26 mg twice-daily is recommended for patients with moderate hepatic impairment (Child-Pugh B classification). Double the dose of Sacubitril & Valsartan every 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
- Mild: No starting dose adjustment is needed for mild hepatic impairment.
- Severe: Use in patients with severe hepatic impairment is not recommended.
Therapeutic Class
Combined antihypertensive preparations
Storage Conditions
Store at room temperature between 20°C to 25°C. Protect from moisture.
* চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Reviews
There are no reviews yet.